BCDA BioCardia

BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025

BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025

SUNNYVALE, Calif., March 21, 2025 (GLOBE NEWSWIRE) -- [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the year ended December 31, 2024 on Wednesday, March 26, 2025, and will host a corporate update conference call on Monday, March 31, 2025 (time and dial-information to be announced). The conference call will follow the presentation, “A Double-blind, Randomized Controlled Trial of an Autologous Cell Therapy in Patients with HFrEF: Principal Results from the CardiAMP-HF Trial,” at the American College of Cardiology 2025 Scientific Sessions in Chicago on March 30, 2025.

About BioCardia®

, headquartered in Sunnyvale, California, is a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP® autologous and CardiALLO™ allogeneic cell therapies are the Company’s biotherapeutic platforms with three cardiac clinical stage product candidates in development. These therapies are enabled by its Helix™ biotherapeutic delivery and Morph® vascular navigation product platforms. For more information visit .



MEDIA CONTACT:
Miranda Peto, Investor Relations
 
(650) 226-0120

INVESTOR CONTACT:
David McClung, Chief Financial Officer
 
(650) 226-0120
EN
21/03/2025

Underlying

BCDABioCardia

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioCardia

 PRESS RELEASE
Free
BCDA BIOCARDIA

BioCardia Announces Positive DSMB Review of CardiALLO Allogeneic Cell ...

BioCardia Announces Positive DSMB Review of CardiALLO Allogeneic Cell Therapy for Heart Failure Phase 1/2 Clinical Trial Independent Data Safety Monitoring Board (DSMB) recommends that the study proceeds as designed based on 30-day data safety assessment of participants treated in low dosage group. The company plans to progress the trial to enrollment of 39 participants in the United States. SUNNYVALE, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary dise...

April 15, 2025 1 EN
 PRESS RELEASE
Free
BCDA BIOCARDIA

BioCardia Initiates Patient Enrollment at Emory University School of M...

BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study CardiAMP HF II is Evaluating the CardiAMP™ Cell Therapy Product for Treating Patients with Ischemic Heart Failure of Reduced Ejection Fraction and Elevated Markers of Cardiac Stress Dr. Arshed Quyyumi, Professor of Medicine, Division of Cardiology, Department of Medicine, Emory University School of Medicine, and Co-Director of the Emory Clinical Cardiovascular Research Institute to Serve as Principal Investigator SUNNYVALE, Calif., April 11, 2025 (GLOBE NEWSWIRE...

April 11, 2025 1 EN
 PRESS RELEASE
Free
BCDA BIOCARDIA

BioCardia’s Conference Call Today, Monday, March 31, 2025 to be Held a...

BioCardia’s Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today SUNNYVALE, Calif., March 31, 2025 (GLOBE NEWSWIRE) --  [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today clarifies that two-year CardiAMP-HF results will be addressed in a conference call scheduled for today, Monday, March 31, 2025 at 4:30pm EDT. The press release earlier this morning incorrectly noted the call would be held at 4:30pm PDT. To access the call today:Participants can register for the conferenc...

March 31, 2025 1 EN
 PRESS RELEASE
Free
BCDA BIOCARDIA

Biocardia Phase 3 CardiAMP-HF Trial of Novel Cardiac Cell Therapy for ...

Biocardia Phase 3 CardiAMP-HF Trial of Novel Cardiac Cell Therapy for Ischemic Heart Failure Shows Increased Survival, Decreased Cardiac Events, and Improved Quality of Life at Two Years Increased survival and reduced major adverse cardiac and cerebrovascular events (MACCE) observed study-wide, despite primary composite efficacy endpoint not reaching statistical significanceStatistically significant improvement in composite outcome measure comprised of survival, MACCE, and quality of life seen in patients suffering from active heart stress (those with elevated NTproBNP and BNP biomarkers) t...

March 31, 2025 1 EN
 PRESS RELEASE
Free
BCDA BIOCARDIA

BioCardia Reports 2024 Business Highlights and Financial Results

BioCardia Reports 2024 Business Highlights and Financial Results SUNNYVALE, Calif., March 26, 2025 (GLOBE NEWSWIRE) --  [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the year ended December 31, 2024 and filed its annual report on Form 10-K with the Securities and Exchange Commission. The Company will host a corporate update conference call on Monday, March 31, 2025 at 4:30 PM ET following its presentation of results from the CardiAMP HF Trial at the Late-Breaking Clini...

March 26, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch